longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Dyne Therapeutics

DYN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Q2 FY2026 Earnings

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Dyne Therapeutics(DYN) the Revenue is 0 (--%), Meet estimate;the EBIT is -181.66 M (-56.89%), Miss estimate;the EPS is -1.08 (-11.34%), Miss estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITMiss expectations
-0.18B56.89%
-0.13B12.50%
-0.05B44.39%
EPSMiss expectations
-1.0811.34%
-0.748722.82%
-0.331334.16%

Revenue

ActualEstimateUnit: USD
qf

EBIT

ActualEstimateUnit: USD
qf

Net income

ActualEstimateUnit: USD
qf

EPS

ActualEstimateUnit: USD
qf